With this in mind, the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) trial examined the effects of pemafibrate, a selective peroxisome proliferator-activated receptor alpha modulator (SPPARM-α), on major CVD events in patients with type 2 diabetes and hypertriglyceridaemia (200–499 mg/dL) and an HDL ≤ 40 mg/dL on stable statin therapy.85 Pemafibrate exhibits greater affinity for PPAR-α than other fibrates, and reduced TGs 40–50% compared with placebo in early phase trials. Here, PPARA is linked to hypertriglyceridemia.